- ASSISTANT PROFESSOR Population Health Science and Policy
CCRA, Association for Clinical Research Professionals (ACRP)
Associate Dean of Research Services
Icahn School of Medicine at Mount Sinai
Director of Regulatory Knowledge & Support
Institutes for Translational Sciences- ConduITS
Director of Operations, Clinical Trials Office
The Tisch Cancer Institute
2008 to present: Clinical and Translational Science Award (CTSA)
2011 to 2012: Outreach Coordination for Recruitment Strategies (FAI)
2009 to 2013: Cardiothoracic Surgery Network (CTSN)
deBoccardo G, Kim J, Schiano T, Gagliardi R. The Burden of Chronic Kidney Disease in Long-Term Liver Transplant Recipients. . Am J Transplant 2008;.
Lucey MR, Abdelmakel MF, Gagliardi R, Granger D, Holt C, Kam I, Klintmalm G, Langnas A, Shetty K, Tzakis A, Woodle ES. A Comparison of Tacrolimus and Cycloporine in Liver Transplantation: Effects on Renal Function and Cardiovascular Risk Status. Am J Transplant 2005; 5: 1111-1119.
Killackey MT, Gondolesi G, Gagliardi R, Falchook A, Schiano T. Implementation of Rapid Steroid Withdrawal Protocol in Liver Transplantation: 9 month follow up of the first 40 patients. Hepatology 2004; 40(4 suppl 1).
Scheiner P, Gagliardi R, Emre DS. Liver Transplantation. In: Chamberlain R, Blumgart L, editors. Hepatobiliary Surgery. Georgetown, TX , Landes Bioscience; 2003.
Lucey MR, Gagliardi R. Impact of Tacrolimus versus Cyclosporine on Long-Term Renal Function and Cardiovascular Risk Following Liver Transplantation. Am J Transplant 2003; 3(suppl 5): 325.
Lucey MR, Gagliardi R. Tacrolimus versus Cyclosporine Following Liver Transplantation: Impact on Long-Term Outcomes in Routine Clinical Practice. Am J Transplant 2003; 3(suppl 5): 326.
Kim-Schluger L, Florman SS, Schiano T, O'Rourke M, Gagliardi R, Drooker M, Emre S, Fishbein TM, Sheiner PA, Schwartz ME, Miller CM. Quality of life after lobectomy for adult liver transplantation. Transplantation 2002; 73(10): 1593-1597.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Gagliardi did not report having any of the following types of financial relationships with industry during 2014 and/or 2015: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
17 East 102 Street Floor West Tower Room 4th floor
New York, NY 10029
17 East 102 Street Floor 4th floor Room 111
New York, NY 10029